FTO and neoplasm: On the “eraser” side, FTO has emerged as a radiosensitization target: genetic and pharmacologic FTO blockade increased DNA damage (reduced RAD51 foci, impaired HR) and improved tumor control by radiotherapy in HNSCC models—without exacerbating mucositis—indicating a widened therapeutic window (146).